Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib
Saumya Jayakumar, Michael S. Middleton, Eric Lawitz, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 1, pp. 133-141
Open Access | Times Cited: 180

Showing 1-25 of 180 citing articles:

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castéra, Mireen Friedrich‐Rust, Rohit Loomba
Gastroenterology (2019) Vol. 156, Iss. 5, pp. 1264-1281.e4
Open Access | Times Cited: 1172
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1144
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel, Stephen A. Harrison, Magdy Elkhashab, et al.
Hepatology (2020) Vol. 72, Iss. 1, pp. 58-71
Closed Access | Times Cited: 266
Advances in non-invasive assessment of hepatic fibrosis
Rohit Loomba, Leon A. Adams
Gut (2020) Vol. 69, Iss. 7, pp. 1343-1352
Open Access | Times Cited: 262
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
Jenny Lee, Yasaman Vali, Jérôme Boursier, et al.
Liver International (2020) Vol. 41, Iss. 2, pp. 261-270
Open Access | Times Cited: 251
Limitations of non-invasive tests for assessment of liver fibrosis
Keyur Patel, Giada Sebastiani
JHEP Reports (2020) Vol. 2, Iss. 2, pp. 100067-100067
Open Access | Times Cited: 228
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice
Jianghua Zhou, Jingjing Cai, Zhi‐Gang She, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 11, pp. 1307-1326
Open Access | Times Cited: 204
Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Jonathan G. Stine, Nagambika Munaganuru, Abbey Barnard, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 11, pp. 2274-2283.e5
Open Access | Times Cited: 166
Imaging biomarkers of NAFLD, NASH, and fibrosis
Veeral Ajmera, Rohit Loomba
Molecular Metabolism (2021) Vol. 50, pp. 101167-101167
Open Access | Times Cited: 150
Quantification of Liver Fat Content with CT and MRI: State of the Art
Jitka Starekova, Diego Hernando, Perry J. Pickhardt, et al.
Radiology (2021) Vol. 301, Iss. 2, pp. 250-262
Open Access | Times Cited: 150
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1475-1486
Open Access | Times Cited: 149
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
Nobuharu Tamaki, Veeral Ajmera, Rohit Loomba
Nature Reviews Endocrinology (2021) Vol. 18, Iss. 1, pp. 55-66
Open Access | Times Cited: 147
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1263-1277
Open Access | Times Cited: 146
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint, Grit Andersen, Paul Hockings, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 9, pp. 1150-1161
Open Access | Times Cited: 143
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 46-56
Closed Access | Times Cited: 95
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants
Veeral Ajmera, Beom Kyung Kim, Kun Yang, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 1079-1089.e5
Open Access | Times Cited: 90
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 54
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 48
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Tracey G. Simon, Robert M. Wilechansky, Stefania Stoyanova, et al.
JAMA (2024) Vol. 331, Iss. 11, pp. 920-920
Open Access | Times Cited: 39
Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH
Rohit Loomba, Brent A. Neuschwander‐Tetri, Arun J. Sanyal, et al.
Hepatology (2020) Vol. 72, Iss. 4, pp. 1219-1229
Open Access | Times Cited: 109
Recent Epidemiology of Nonalcoholic Fatty Liver Disease
Soumya Murag, Aijaz Ahmed, Donghee Kim
Gut and Liver (2020) Vol. 15, Iss. 2, pp. 206-216
Open Access | Times Cited: 92
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Vlad Ratziu, Mary E. Rinella, Brent A. Neuschwander‐Tetri, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 506-517
Closed Access | Times Cited: 81
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
Nobuharu Tamaki, Nagambika Munaganuru, Jinho Jung, et al.
Gut (2021) Vol. 71, Iss. 5, pp. 983-990
Open Access | Times Cited: 80
MR elastography of liver: current status and future perspectives
Ilkay S. Idılman, Jiahui Li, Meng Yin, et al.
Abdominal Radiology (2020) Vol. 45, Iss. 11, pp. 3444-3462
Open Access | Times Cited: 76
Page 1 - Next Page

Scroll to top